23 completed, 7 recruiting, 7 terminated, 5 unknown. 51 Phase 1, 17 Phase 2.
Follow MDS: new trials by email Literature Review of MDS trials Research Report on MDS
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pacritinib With Aza for Upfront Myelodysplastic Syndrome Pacritinib, Azacitidine, Bone Marrow Biopsy and Aspirate - Myelodysplastic Syndromes, MDS | Phase 1 / Phase 2 | Withdrawn | Thomas Jefferson University | 2026-09-01 | 2026-08-17 | |
| QH101 Cell Therapy Relapsed/Refractory(R/R) Acute Myeloid Leukemia(AML) and Myelodysplastic Syndromes(MDS) Allogeneic TCR-enhanced γδ T cell(QH101), Fludarabine (FLU), Cyclophosphamide (CTX) - MDS, AML | Phase 1 | Not yet recruiting | Anhui Provincial Hospital | 9 | 2025-08-15 | 2025-08-20 |
| Safety of MT-401-OTS in Patients With Relapsed AML or MDS MT-401-OTS - Acute Myeloid Leukemia, in Relapse, MDS | Phase 1 | Recruiting | Marker Therapeutics, Inc. | 40 | 2025-06-16 | 2025-12-16 |
| A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS) Decitabine - MDS | Phase 1 | Recruiting | Treebough Therapies | 20 | 2025-06-03 | 2026-01-15 |
| Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDS Eganelisib, Eganelisib in combination with cytarabine, Eganelisib in combination with azacitidine - AML, Adult, MDS | Phase 1 | Recruiting | Stelexis BioSciences | 105 | 2025-04-28 | 2026-10-20 |
| A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies CG009301 for Injection - Leukemia, AML | Phase 1 | Recruiting | Cullgen (Shanghai),Inc | 45 | 2025-04-17 | 2026-01-16 |
| BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS SOC + BSB-1001 Dose Escalation Cohort, SOC+BSB-1001 Expansion Dose - AML, Adult Recurrent, ALL, Recurrent, Adult | Phase 1 / Phase 2 | Terminated | BlueSphere Bio, Inc | 2 | 2025-02-04 | 2026-09-10 |
| CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies Fludarabine, Cyclophosphamide, CD70-CAR T cell infusion (Autologous) - Hematologic Malignancy, ALL, Childhood | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 18 | 2024-10-16 | 2026-01-23 |
| To Evaluate the Phase I Clinical Study of XZB-0004 in Patients With AML and MDS XZB-0004 - AML, MDS | Phase 1 | Unknown | Xuanzhu Biopharmaceutical Co., Ltd. | 82 | 2023-02-01 | 2023-02-23 |
| A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS) LYT-200, Venetoclax, Azacitidine - AML, Adult Recurrent, MDS | Phase 1 | Completed | PureTech | 101 | 2022-12-12 | 2026-05-06 |
| Venetoclax in Patients With MDS or AML in Relapse After AHSCT venetoclax + azacitidine +/- donor lymphocyte infusion - MDS, AML | Phase 1 / Phase 2 | Active not recruiting | Groupe Francophone des Myelodysplasies | 55 | 2022-11-23 | 2026-03-12 |
| Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies Tagraxofusp, Fludarabine, Cytarabine - Hematologic Malignancy, AML | Phase 1 | Recruiting | Therapeutic Advances in Childhood Leukemia Consortium | 54 | 2022-11-11 | 2024-12-06 |
| A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA) SOC + TSC-101, Control, SOC + TSC-100 - AML, MDS | Phase 1 | Active not recruiting | TScan Therapeutics, Inc. | 310 | 2022-11-01 | 2026-10-05 |
| Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA Luspatercept Injection [Reblozyl], Eprex - MDS, Myelodysplastic Syndromes | Phase 1 / Phase 2 | Recruiting | Groupe Francophone des Myelodysplasies | 150 | 2022-05-18 | 2026-09-29 |
| Safety and Efficacy of Allogeneic NK Cell Infusions in Patients With Relapsed/Refractory AML and High Risk MDS DVX201 - AML, Adult Recurrent, MDS | Phase 1 | Completed | Coeptis Therapeutics | 8 | 2021-12-15 | 2024-07-19 |
| APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS) APR-548 + Azacitidine - MDS, Myelodysplastic Syndromes | Phase 1 | Terminated | Aprea Therapeutics | 4 | 2021-09-20 | 2025-03-10 |
| A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML CFI-400945, Azacitidine - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 / Phase 2 | Active not recruiting | Treadwell Therapeutics, Inc | 72 | 2021-04-16 | 2025-05-18 |
| A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS APG-115, 5-azacitidine - AML, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | Ascentage Pharma Group Inc. | 69 | 2020-12-04 | 2024-02-01 |
| NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS NKX101 - CAR NK cell therapy - Relapsed/Refractory AML, AML, Adult | Phase 1 | Active not recruiting | Nkarta, Inc. | 61 | 2020-09-21 | 2024-12-27 |
| A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) SHR-1702 - AML, MDS | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 31 | 2020-09-10 | 2023-08-24 |
Showing 20 of 51. Sign in to see all of them.
Leukemia, Myeloid, Acute (20) · Myelodysplastic Syndromes (15) · Leukemia (6) · Hematologic Neoplasms (5) · Hodgkin Disease (5) · Multiple Myeloma (5) · Recurrence (5) · Leukemia, Myelomonocytic, Chronic (4) · Lymphoma (4) · Lymphoma, Non-Hodgkin (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Myeloproliferative Disorders (3) · Graft vs Host Disease (2) · Primary Myelofibrosis (2) · Anemia, Aplastic (1)
Hemic and Lymphatic Diseases (36) · Hematologic Diseases (35) · Neoplasms (30) · Neoplasms by Histologic Type (28) · Leukemia, Myeloid (21) · Bone Marrow Diseases (20) · Leukemia (20) · Immune System Diseases (13) · Disease Attributes (11) · Immunoproliferative Disorders (11) · Lymphoproliferative Disorders (11) · Pathologic Processes (11) · Pathological Conditions, Signs and Symptoms (11) · Lymphatic Diseases (10) · Chronic Disease (6)
Azacitidine (14) · fludarabine (7) · Cyclophosphamide (6) · Decitabine (6) · Cytarabine (5) · Dexamethasone (3) · fludarabine phosphate (3) · venetoclax (3) · Calcium Dobesilate (2) · Granulocyte Colony-Stimulating Factor (2) · Mesna (2) · Mycophenolic Acid (2) · Sirolimus (2) · Tacrolimus (2) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (1)
Groupe Francophone des Myelodysplasies (4) · Astex Pharmaceuticals, Inc. (2) · Amgen (1) · Anhui Provincial Hospital (1) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · Aprea Therapeutics (1) · Aptevo Research and Development LLC (1) · Ascentage Pharma Group Inc. (1) · BlueSphere Bio, Inc (1) · Celgene (1) · Celyad Oncology SA (1) · Chinese PLA General Hospital (1) · Coeptis Therapeutics (1) · Cullgen (Shanghai),Inc (1) · Cyclacel Pharmaceuticals, Inc. (1)
United States (39) · China (5) · France (5) · Canada (3) · Australia (2) · Belgium (2) · Italy (2) · Georgia (1) · Greece (1) · Hong Kong (1) · Japan (1) · Spain (1)
Gautam Borthakur, MD (3) · Adam Lamble, MD (1) · Aleksandra Filipovic, MD, PhD. (1) · Chetan Jeurkar, DO (1) · David A Rizzieri, MD (1) · David Porter, MD (1) · David Shook, MD (1) · Elizabeth Hexner, MD (1) · Emmanuel Besa, MD (1) · Felipe Suarez, MD (1) · Frederic Lehmann, MD (1) · Guillermo Garcia-Manero, MD (1) · James Lowder, MD (1) · Jay Backstrom, MD (1)
PMID 23012326, PMID 24002496, PMID 26296954, PMID 26858124, PMID 28881839, PMID 30926081, PMID 31060979, PMID 31331399, PMID 32264726, PMID 32285126, PMID 32645016, PMID 34439266, PMID 34771451, PMID 38114624